| Patient | Vincent van Gogh |
|---|---|
| Date of birth | 1990-03-30 |
| Identifiers | MRN HR-NI010-SYN; SSN (made up) 000-10-3198 |
| Document date | 2026-07-20 |
| Author | Elise Verhoeven, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-month review: diagnosis, relapse prevention, movement check, and alcohol. [S]
Mr. van Gogh returns six months after his first visit. He has had no psychotic symptoms for more than four months and no racing ideas since the spring. He takes aripiprazole 10 mg and naltrexone daily. He sleeps seven hours. He is painting every day and preparing work for a small exhibition. He drinks a glass of wine with dinner on some days and none on others. His mood is good. The care coordinator's monthly PHQ-9 calls have been in the low range. He has had no thoughts of suicide or self-harm. His hepatitis C antibody from the preventive visit was nonreactive. [S]
| Element | Detail |
|---|---|
| Psychotic symptoms | None for more than four months |
| Mood | Good; PHQ-9 3 |
| Sleep | Seven hours at regular times |
| Alcohol | A glass of wine with dinner on some days |
| Hepatitis C antibody | Nonreactive |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight stable |
| Neurological | Negative | No restlessness, stiffness, tremor, abnormal movements, or seizures |
| Psychiatric | Negative | No voices, suspiciousness, or racing ideas; mood good; no thoughts of suicide or self-harm |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Aripiprazole 10 mg oral tablet, one tablet by mouth once daily (started in hospital) | One tablet by mouth once daily | Oral route | 2026-01-05 to 2026-02-02 | completed | S |
| Aripiprazole 15 mg oral tablet, one tablet by mouth once daily | One tablet by mouth once daily | Oral route | 2026-02-02 to 2026-02-16 | completed | S |
| Naltrexone 50 mg oral tablet, one tablet by mouth once daily | One tablet by mouth once daily | Oral route | 2026-02-02 | active | S |
| Thiamine 100 mg oral tablet, one tablet by mouth daily (started in hospital) | One tablet by mouth daily | Oral route | 2026-01-05 to 2026-07-20 | completed | S |
| Aripiprazole 10 mg oral tablet, one tablet by mouth once daily | One tablet by mouth once daily | Oral route | 2026-02-16 | active | S |
| Propranolol 10 mg oral tablet, one tablet by mouth twice daily for akathisia | One tablet by mouth twice daily | Oral route | 2026-02-16 to 2026-03-02 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-07-20 | Body height | 170 | cm | S |
| 2026-07-20 | Body weight | 65.4 | kg | S |
| 2026-07-20 | Body mass index (BMI) [Ratio] | 22.6 | kg/m2 | S |
| 2026-07-20 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-07-20 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-07-20 | Heart rate | 70 | /min | S |
| 2026-07-20 | Respiratory rate | 14 | /min | S |
| 2026-07-20 | Body temperature | 36.6 | Cel | S |
| 2026-07-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-07-20 | Leukocytes [#/volume] in Blood by Automated count | 6.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-07-20 | Hemoglobin [Mass/volume] in Blood | 14.6 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-07-20 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 95 | fL | 80-100 fL | Normal | S |
| 2026-07-20 | Platelets [#/volume] in Blood by Automated count | 214 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-07-20 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 | U/L | 10-40 U/L | Normal | S |
| 2026-07-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 7-56 U/L | Normal | S |
| 2026-07-20 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 36 | U/L | 8-61 U/L | Normal | S |
| 2026-07-20 | Phosphatidylethanol [Mass/volume] in Blood | 16 | ng/mL | Below 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinking | Normal | S |
| 2026-07-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S |
Vital signs recorded on 2026-07-20; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 65.4 kg; blood pressure 118/76, pulse 70 |
| Neurological | AIMS score 0: no abnormal movements of the face, lips, jaw, tongue, limbs, or trunk; no akathisia or rigidity |
| Psychiatric | Euthymic and engaged; organized; no psychotic features |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| First episode of psychosis with mood features: weeks of very little sleep, intense work and expansive plans, then acute confusion, hallucinations and suspiciousness with self-injury, and low mood since discharge. Diagnosis provisional; differential: bipolar I disorder with psychotic features, brief psychotic or schizophreniform disorder, alcohol withdrawal delirium or alcohol-induced psychotic disorder, and psychosis related to focal epilepsy. Synthetic modern episode linked to his documented first crisis | active | provisional | F29 | S — Synthetic modern coding of the documented first crisis. Unspecified psychosis is coded because the cause is not yet established; the retrospective diagnoses stay in the claims. |
| Alcohol use disorder, moderate (heavy daily wine and anise spirits before the episode); synthetic modern episode linked to his documented heavy drinking | active | confirmed | F10.20 | S — Synthetic modern coding of the documented drinking and its retrospective interpretation. |
| Self-injury to the left ear during the acute confusional episode, without suicidal intent; wound healed after surgical care in hospital | active | confirmed | Z91.52 | S — Synthetic modern coding of the documented injury; no detail of the injury is recorded. |
| Akathisia from aripiprazole, two weeks after the dose was increased to 15 mg; treated by returning to 10 mg and short-term propranolol; resolved | resolved | confirmed | G25.71 | S — Synthetic medication side effect; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Antipsychotic dose, adherence, and response | Every visit | Completed today | Aripiprazole 10 mg; full adherence; full remission |
| Survey | Psychotic and mood symptoms, and early warning signs | Every visit | Completed today | No psychotic or mood symptoms; no early warning signs |
| Examination | Akathisia, parkinsonism, and sedation | Every visit in the first months and after any dose change | Completed today | None |
| Examination | Abnormal Involuntary Movement Scale (AIMS) | Baseline, then every 6 months | Completed today | AIMS score 0 at six months; repeat in six months |
| Examination | Weight and BMI | Every visit for 6 months after starting, then quarterly (CMID: baseline, 4, 8, and 12 weeks, then quarterly) | Completed today | 65.4 kg, up 2.2% from intake; quarterly from now |
| Examination | Blood pressure | Baseline, 12 weeks, then yearly | Completed today | 118/76 |
| Laboratory | Fasting glucose and A1c | Baseline, 12 weeks to 4 months, then yearly | Up to date | Normal at the three-month visit; next in a year |
| Laboratory | Fasting lipid panel | Baseline, 12 weeks to 4 months, then yearly | Up to date | Normal at the three-month visit; next in a year |
| Survey | Depression measure (PHQ-9) | Monthly during acute treatment, every 2 to 4 weeks in continuation, then periodically | Completed today | PHQ-9 3, from 13 at intake: remission |
| Survey | Mood Disorder Questionnaire | When a new depressive episode is evaluated | Not indicated | No depressive episode now; the possibility of bipolar disorder is followed through the mood history at each visit |
| Survey | Suicide-risk review, safety plan, lethal means, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; safety plan and psychiatric advance directive current; the 988 Suicide & Crisis Lifeline in his phone |
| Self-management | Sleep | Every visit | Completed today | Seven hours at regular times |
| Survey | Drinking (AUDIT-C and PEth) | PEth at intake and at each check while drinking continues; AUDIT-C yearly | Completed today | PEth 16 ng/mL; AUDIT-C 3 at the preventive visit |
| Medication safety | Naltrexone: liver tests and opioid exposure | Liver tests before starting, then at 1 to 3 months and every 6 to 12 months | Completed today | AST 27, ALT 26, GGT 36 U/L, normal |
| Laboratory | Blood count | At intake and with liver tests while drinking | Completed today | White cells 6.4, hemoglobin 14.6 g/dL, MCV 95 fL (from 102), platelets 214 |
| Medication safety | Thiamine | While drinking heavily | Completed today | Stopped today |
| Self-management | Hepatitis B vaccine | Two doses at least four weeks apart | Completed today | Dose 2 given today; series complete |
| Self-management | Coordinated specialty care engagement | Ongoing, for up to two to three years | Completed today | Therapist every two weeks; peer specialist monthly; exhibition planned |
Goal progress:
Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2 [S]
Guideline basis: The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition (2020); Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018); Consensus development conference on antipsychotic drugs and obesity and diabetes (2004); Recovery After an Initial Schizophrenia Episode (RAISE): coordinated specialty care for first-episode psychosis (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); Adult Immunization Schedule by Medical Condition and Other Indication (2026)
Follow-up: Visits every three months with weight and the PHQ-9. Psychiatry review with Dr. Feld near the one-year mark about the length of antipsychotic treatment. AIMS in six months; glucose, A1c and lipids in a year. Influenza and COVID-19 vaccines in the autumn. [S]